… of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with type 2 diabetes.
… We identified 32,078 rivaroxaban and 83,971 warfarin patients with NVAF and comorbid T2D …

… The trial found reduced-dose rivaroxaban to preserve the treatment effect of warfarin with …
the effectiveness and safety of rivaroxaban vs. warfarin among NVAF patients stratified by renal …

… and systemic embolism (SE) in patients with NVAF in November 2011 based on the ROCKET-…
of rivaroxaban compared with warfarin in NVAF patients with both obesity and diabetes. …

… and safety of rivaroxaban versus warfarin in nonvalvular AF (NVAF) patients with concomitant
OSA… We included adults with NVAF and OSA at baseline, newly initiated on rivaroxaban or …

… , dabigatran, and rivaroxaban with warfarin in Asians with NVAF as a nationwide … patients
receiving the apixaban, dabigatran, and rivaroxaban and 19 375 patients prescribed warfarin …

… We report the coagulation status in Japanese NVAF patients treated with rivaroxaban and
warfarin in real-world clinical practice. Our preliminary results indicate that the level of the …

… characteristics–medication use, dosage, and switching from warfarin–patients treated
with rivaroxaban were significantly more likely to have any bleeding (HR: 1.35, 95% CI: 1.26–1.45) …

… total of 7841 NVAF patients treated with warfarin and 3509 NVAF patients treated with
rivaroxaban were eligible to … A total of 2468 NVAF patients (31.5% of eligible patients) treated with …

… the use of apixaban and rivaroxaban versus warfarin in NVAF patients with ESRD and/or …
colleagues16 compared apixaban to warfarin in NVAF patients undergoing dialysis using data …

… taking 10 mg rivaroxaban, and 16,000 NVAF patients taking warfarin. Inverse probability
of weighting using propensity scores was used to balance covariates across study groups. …